Beta Bionics is a technology company.
Beta Bionics has raised $120.0M across 2 funding rounds.
Beta Bionics has raised $120.0M in total across 2 funding rounds.
Beta Bionics is a medical technology company developing automated insulin delivery systems for people with type 1 diabetes, primarily through its flagship iLet Bionic Pancreas. The iLet automates insulin dosing using continuous glucose monitor (CGM) data from Dexcom or FreeStyle Libre 3 Plus sensors, requiring only the user's weight as input—no carb counting, correction factors, or preset basal rates—thus simplifying diabetes management and reducing daily burden for patients aged 6 and older.[1][2][3][4][5][6] It serves individuals with type 1 diabetes and their caregivers, addressing the challenge that fewer than 1 in 5 U.S. patients meet American Diabetes Association therapy goals, with recent growth including FDA clearance in 2023 and a Nasdaq IPO.[2][5]
Beta Bionics originated from the personal tragedy and determination of cofounder Ed Damiano, a Boston University biomedical engineering research professor, whose infant son developed type 1 diabetes in 2002, inspiring over two decades of research starting in Damiano's BU lab.[2][5] The company was formally founded on October 21, 2015, as a public benefit corporation in Irvine, California, with additional locations in Massachusetts, building on 12+ years of clinical research and 20 pre-pivotal trials to commercialize the academic bionic pancreas platform into the integrated iLet device.[1][2][5][8] Early traction included FDA clearance for the iLet in 2023 for ages 6+, culminating in a major milestone with its Nasdaq IPO, marking its transition from lab innovation to market-ready product.[2]
Beta Bionics stands out in the closed-loop diabetes device market through these key strengths:
Beta Bionics rides the wave of closed-loop automated insulin delivery systems, combining CGMs, insulin pumps, and AI-driven algorithms to mimic a healthy pancreas amid rising diabetes prevalence and tech maturation in continuous monitoring.[1][2][8] Timing is ideal post-2023 FDA approval and IPO, capitalizing on market forces like interoperable CGM ecosystems (e.g., Dexcom, Abbott partnerships) and demand for burden-reducing tools, as current therapies leave most patients short of targets.[4][5] It influences the ecosystem by pushing commercialization of academic research, fostering competition that accelerates adoption—named a market challenger—and expanding to underserved groups like children, while advancing multi-hormone (insulin + glucagon) and patch pump tech.[1][2]
Beta Bionics is poised for expansion with its Nasdaq-listed status fueling R&D into a patch pump and two-hormone bionic pancreas (adding glucagon for full glucose control), potentially transforming type 1 diabetes care beyond insulin-only systems.[2] Trends like AI personalization, CGM interoperability, and payer coverage for automated devices will propel growth, evolving its influence from niche innovator to ecosystem leader serving the "multitudes" with type 1 diabetes.[2][5] This builds directly on its origin as a father's quest for his son, now scaling life-changing simplicity to millions.
Beta Bionics has raised $120.0M in total across 2 funding rounds.
Beta Bionics's investors include RTW Investments.
Beta Bionics has raised $120.0M across 2 funding rounds. Most recently, it raised $57.0M Series C in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $57.0M Series C | RTW Investments | |
| Jan 1, 2019 | $63.0M Series B | RTW Investments |